Several promising compounds with therapeutic activity in preclinical systems have been reported and have recently advanced into early clinical trials.
For instance, inhibitors of EZH2 - a histone 3 lysine 27 (H3K27) methyltransferase that is overexpressed in a number of solid tumors and is the site of recurrent gain-of-function mutations in lymphoma - are raising considerable interest as potential anti-cancer agents, and have recently advanced to the clinic [ 5].
The field of optical refrigeration of lanthanide-doped solids emerged in 1994 with the first laser cooling of an Yb3 +-doped fluoride glass, and it has recently advanced into the cryogenic regime with the demonstration of cooling Yb3 +-doped fluoride crystals to sub-100 K temperatures.
Our fundamental biochemical knowledge of starch biosynthesis has recently advanced, and this new information could be exploited to create novel variability in carbohydrate polymers in cereal grains.
The neddylation pathway has been recognized as an attractive anticancer target in several malignancies, and its selective inhibitor, MLN4924, has recently advanced to clinical development.
The technology behind modern cryostats has recently advanced significantly, and the very expensive liquid helium is not even necessary anymore". Another interesting angle is that this architecture isn't limited to just superconductors.
After initial Phase I trials confirmed the safety, dosimetry, and biodistribution of this PET tracer, it has recently advanced to Phase IIa trials [ 107].
Medical information technology has recently advanced in many countries, and enormous amounts of clinical data are already stored as electronic medical records (EMRs).
Interpreting sexual asexual interactions though has recently advanced owing to methodological design, increased taxon sampling and choice of model organisms.
Several groups have been advancing towards clinical trials, but the work on Telomelysin, OBP-301 an attenuated adenovirus 5 vector in which the hTERT proximal promoter drives the expression of E1A and E1B genes linked with an internal ribosome entry site (Fujiwara et al, 2007), has recently advanced to clinical trials.
